

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



## **ALIBABA HEALTH INFORMATION TECHNOLOGY LIMITED**

**阿里健康信息技術有限公司**

*(Incorporated in Bermuda with limited liability)*

**(Stock code: 00241)**

### **SUPPLEMENTAL ANNOUNCEMENT RENEWAL OF NON-EXEMPT CONTINUING CONNECTED TRANSACTIONS**

References are made to (i) the announcement of Alibaba Health Information Technology Limited (the “**Company**”) dated February 7, 2020 and the circular of the Company dated March 9, 2020 (the “**Circular**”) in respect of the renewal of non-exempt continuing connected transactions contemplated under the 2021 Logistics Services Framework Agreement, the 2021 Platform Services Framework Agreement and the 2021 Advertising Services Framework Agreement (together, the “**2021 CCT Agreements**”); (ii) the announcement of the Company dated March 29, 2020 in respect of the proposed adjournment of the special general meeting (the “**SGM**”) scheduled to be held at Holiday Inn Express Hong Kong Causeway Bay, Meeting Room I & II, 7/F, 33 Sharp Street East, Causeway Bay, Hong Kong on Monday, March 30, 2020 at 10:30 a.m.; and (iii) the announcement of the Company dated March 30, 2020 in respect of the passing of the resolution by the shareholders of the Company (the “**Shareholders**”) to adjourn the SGM to a date, time and venue to be determined by the board of directors of the Company in due course (the “**Adjourned SGM**”). Unless otherwise specified, capitalized terms used herein shall have the meanings given to them in the Circular.

In view of the adjournment of the SGM and to ensure compliance with the Prevention and Control of Disease (Prohibition on Group Gathering) Regulation (Chapter 599G of the Laws of Hong Kong) and the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”), on April 1, 2020, the Company and its relevant Subsidiaries (as applicable) entered into a supplemental agreement with each of the respective other part(ies) of each of the 2021 CCT Agreements (together, the “**Supplemental Agreements**”), pursuant to which the parties (the “**Parties**”) to each of the 2021 CCT Agreements, as supplemented by the Supplemental Agreements, agreed that

the effective date of each respective 2021 CCT Agreement shall commence from April 1, 2020 (the “**Effective Date**”) and end on March 31, 2021. The Parties further agreed that, for the period commencing from the Effective Date and ending on the date on which independent Shareholders’ approval is obtained at the Adjourned SGM in connection with the 2021 CCT Agreements, the transactions contemplated thereunder and the annual caps related thereto (the “**Interim Period**”), the total service fees payable by the Group under each of the 2021 CCT Agreements (the “**Interim Transaction Amount**”) shall not be more than RMB254.7 million, such that each of the applicable percentage ratios (other than the profit ratio) calculated with reference to the Interim Transaction Amount incurred under each of the 2021 CCT Agreements will be less than 5% during such Interim Period. Save as disclosed above, all the other terms of the 2021 CCT Agreements remain unchanged and are in full force and effect.

The Company will, as soon as practicable, issue a new notice setting out the date, time and venue of the Adjourned SGM. The resolutions as set out in the notice of special general meeting of the Company dated March 9, 2020 will remain unchanged, and will be proposed and transacted at the Adjourned SGM.

By Order of the Board  
**ALIBABA HEALTH INFORMATION TECHNOLOGY LIMITED**  
**ZHU Shunyan**  
*Chairman and Chief Executive Officer*

Hong Kong, April 1, 2020

*As at the date of this announcement, the Board comprises eight Directors, of whom (i) two are executive Directors, namely, Mr. ZHU Shunyan and Mr. WANG Qiang; (ii) three are non-executive Directors, namely Mr. WU Yongming, Mr. WANG Lei and Mr. XU Hong; and (iii) three are independent non-executive Directors, namely Mr. LUO Tong, Mr. WONG King On, Samuel and Ms. HUANG Yi Fei (Vanessa).*